Cathy Bradley
Concepts (497)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Neoplasms | 69 | 2024 | 2455 | 10.460 |
Why?
| Employment | 40 | 2024 | 167 | 10.420 |
Why?
| Medicaid | 37 | 2023 | 431 | 8.230 |
Why?
| Breast Neoplasms | 49 | 2024 | 2133 | 5.800 |
Why?
| Cancer Survivors | 16 | 2024 | 257 | 5.110 |
Why?
| Insurance Coverage | 22 | 2024 | 219 | 4.580 |
Why?
| Medicare | 36 | 2025 | 708 | 4.360 |
Why?
| Insurance, Health | 20 | 2024 | 267 | 3.900 |
Why?
| Cost of Illness | 14 | 2024 | 277 | 3.490 |
Why?
| SEER Program | 22 | 2024 | 202 | 3.330 |
Why?
| Poverty | 13 | 2022 | 499 | 3.010 |
Why?
| Healthcare Disparities | 14 | 2020 | 578 | 2.630 |
Why?
| Colorectal Neoplasms | 16 | 2025 | 749 | 2.610 |
Why?
| Medically Uninsured | 12 | 2020 | 127 | 2.600 |
Why?
| Health Services Accessibility | 18 | 2024 | 903 | 2.580 |
Why?
| United States | 96 | 2025 | 13871 | 2.540 |
Why?
| Uterine Cervical Neoplasms | 7 | 2020 | 230 | 2.480 |
Why?
| Early Detection of Cancer | 10 | 2024 | 370 | 2.340 |
Why?
| Survivors | 17 | 2022 | 460 | 2.260 |
Why?
| Medical Oncology | 6 | 2024 | 269 | 2.190 |
Why?
| Registries | 31 | 2023 | 1899 | 2.060 |
Why?
| Health Care Costs | 14 | 2024 | 367 | 1.940 |
Why?
| Health Benefit Plans, Employee | 5 | 2022 | 22 | 1.930 |
Why?
| Antineoplastic Agents | 9 | 2025 | 2046 | 1.920 |
Why?
| Carcinoma, Non-Small-Cell Lung | 6 | 2025 | 1049 | 1.900 |
Why?
| Humans | 199 | 2025 | 129627 | 1.880 |
Why?
| Survivorship | 4 | 2022 | 47 | 1.690 |
Why?
| Caregivers | 6 | 2023 | 806 | 1.680 |
Why?
| Drug Costs | 4 | 2025 | 100 | 1.650 |
Why?
| Lung Neoplasms | 11 | 2025 | 2342 | 1.570 |
Why?
| Health Care Reform | 4 | 2021 | 101 | 1.530 |
Why?
| Female | 127 | 2025 | 68735 | 1.390 |
Why?
| Aged | 73 | 2025 | 22061 | 1.350 |
Why?
| Colonic Neoplasms | 5 | 2016 | 242 | 1.330 |
Why?
| Mental Health | 4 | 2023 | 688 | 1.260 |
Why?
| Research | 6 | 2022 | 419 | 1.260 |
Why?
| Socioeconomic Factors | 20 | 2022 | 1213 | 1.240 |
Why?
| Policy | 4 | 2024 | 143 | 1.240 |
Why?
| Michigan | 24 | 2015 | 104 | 1.230 |
Why?
| Middle Aged | 74 | 2024 | 31136 | 1.220 |
Why?
| Prescription Drugs | 2 | 2023 | 112 | 1.170 |
Why?
| Income | 8 | 2024 | 188 | 1.160 |
Why?
| Neoplasm Staging | 17 | 2022 | 1282 | 1.140 |
Why?
| Prostatic Neoplasms | 10 | 2022 | 998 | 1.130 |
Why?
| Efficiency | 7 | 2016 | 91 | 1.120 |
Why?
| Aged, 80 and over | 37 | 2025 | 7052 | 1.110 |
Why?
| Health Status | 10 | 2013 | 756 | 1.100 |
Why?
| Male | 93 | 2025 | 63671 | 1.090 |
Why?
| Health Status Disparities | 2 | 2023 | 256 | 1.070 |
Why?
| Medical Record Linkage | 2 | 2021 | 61 | 1.040 |
Why?
| Papanicolaou Test | 2 | 2017 | 42 | 1.010 |
Why?
| Adult | 66 | 2024 | 35600 | 1.010 |
Why?
| Primary Health Care | 6 | 2023 | 1686 | 0.960 |
Why?
| Motivation | 2 | 2020 | 547 | 0.930 |
Why?
| Cancer Care Facilities | 4 | 2024 | 32 | 0.910 |
Why?
| Safety-net Providers | 3 | 2017 | 110 | 0.910 |
Why?
| Occupational Medicine | 1 | 2024 | 10 | 0.910 |
Why?
| Patient Acceptance of Health Care | 4 | 2018 | 761 | 0.910 |
Why?
| Medicare Part C | 1 | 2025 | 28 | 0.890 |
Why?
| Communication | 3 | 2024 | 838 | 0.870 |
Why?
| Eligibility Determination | 5 | 2018 | 63 | 0.850 |
Why?
| Comorbidity | 12 | 2019 | 1547 | 0.840 |
Why?
| Colonoscopy | 4 | 2019 | 238 | 0.810 |
Why?
| Health Expenditures | 8 | 2023 | 180 | 0.800 |
Why?
| Mass Screening | 10 | 2022 | 1190 | 0.800 |
Why?
| Return to Work | 4 | 2022 | 18 | 0.790 |
Why?
| Absenteeism | 4 | 2013 | 47 | 0.770 |
Why?
| Virginia | 7 | 2018 | 60 | 0.750 |
Why?
| Focus Groups | 1 | 2024 | 450 | 0.750 |
Why?
| Occupational Health | 1 | 2024 | 192 | 0.740 |
Why?
| Quality of Life | 6 | 2023 | 2688 | 0.740 |
Why?
| Workplace | 4 | 2021 | 247 | 0.720 |
Why?
| Mammography | 5 | 2024 | 146 | 0.690 |
Why?
| Health Equity | 1 | 2022 | 87 | 0.690 |
Why?
| Medication Adherence | 2 | 2023 | 558 | 0.690 |
Why?
| Cost Sharing | 1 | 2020 | 14 | 0.660 |
Why?
| Perioperative Care | 1 | 2021 | 151 | 0.660 |
Why?
| Models, Economic | 2 | 2011 | 53 | 0.660 |
Why?
| Information Dissemination | 1 | 2022 | 205 | 0.650 |
Why?
| Public Health | 1 | 2024 | 487 | 0.640 |
Why?
| Chemotherapy, Adjuvant | 7 | 2023 | 377 | 0.630 |
Why?
| Young Adult | 24 | 2024 | 12455 | 0.620 |
Why?
| Preventive Health Services | 5 | 2023 | 145 | 0.610 |
Why?
| Retirement | 5 | 2022 | 26 | 0.610 |
Why?
| Health Planning Guidelines | 1 | 2018 | 25 | 0.610 |
Why?
| Health Facilities | 1 | 2019 | 80 | 0.600 |
Why?
| Spouses | 3 | 2017 | 101 | 0.600 |
Why?
| Cost-Benefit Analysis | 9 | 2024 | 569 | 0.590 |
Why?
| Quality Indicators, Health Care | 1 | 2020 | 298 | 0.580 |
Why?
| Diagnostic Imaging | 1 | 2020 | 325 | 0.570 |
Why?
| Survival Analysis | 10 | 2019 | 1269 | 0.570 |
Why?
| Reimbursement, Incentive | 1 | 2017 | 35 | 0.550 |
Why?
| Healthy People Programs | 1 | 2016 | 8 | 0.520 |
Why?
| Occupational Health Services | 2 | 2016 | 31 | 0.520 |
Why?
| Job Satisfaction | 3 | 2013 | 201 | 0.520 |
Why?
| Bevacizumab | 1 | 2017 | 128 | 0.510 |
Why?
| Logistic Models | 13 | 2023 | 1986 | 0.510 |
Why?
| Hematopoietic Stem Cell Transplantation | 1 | 2021 | 576 | 0.500 |
Why?
| Job Description | 2 | 2013 | 14 | 0.500 |
Why?
| Outpatients | 1 | 2019 | 373 | 0.500 |
Why?
| Triple Negative Breast Neoplasms | 3 | 2023 | 193 | 0.490 |
Why?
| Massachusetts | 4 | 2021 | 159 | 0.490 |
Why?
| Length of Stay | 6 | 2012 | 1122 | 0.490 |
Why?
| Chronic Pain | 1 | 2019 | 253 | 0.480 |
Why?
| Rectal Neoplasms | 1 | 2016 | 134 | 0.470 |
Why?
| Nursing Homes | 4 | 2013 | 157 | 0.460 |
Why?
| Fee-for-Service Plans | 4 | 2023 | 87 | 0.460 |
Why?
| State Government | 3 | 2014 | 43 | 0.460 |
Why?
| Longitudinal Studies | 11 | 2022 | 2720 | 0.460 |
Why?
| Vaginal Smears | 1 | 2014 | 55 | 0.450 |
Why?
| Mouth Neoplasms | 3 | 2019 | 85 | 0.440 |
Why?
| Emergency Treatment | 1 | 2015 | 112 | 0.430 |
Why?
| General Practice | 1 | 2014 | 28 | 0.430 |
Why?
| Health Services Research | 4 | 2010 | 391 | 0.430 |
Why?
| Sick Leave | 2 | 2019 | 11 | 0.420 |
Why?
| Health Personnel | 3 | 2022 | 653 | 0.420 |
Why?
| Delivery of Health Care | 5 | 2024 | 898 | 0.420 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2023 | 1560 | 0.400 |
Why?
| Behavioral Risk Factor Surveillance System | 4 | 2017 | 49 | 0.400 |
Why?
| Sickness Impact Profile | 1 | 2013 | 55 | 0.400 |
Why?
| Databases, Factual | 7 | 2021 | 1269 | 0.400 |
Why?
| Insurance Claim Review | 2 | 2010 | 64 | 0.390 |
Why?
| Marital Status | 3 | 2007 | 44 | 0.390 |
Why?
| Value of Life | 2 | 2008 | 17 | 0.390 |
Why?
| Homes for the Aged | 2 | 2013 | 27 | 0.380 |
Why?
| Work | 3 | 2010 | 17 | 0.380 |
Why?
| Survival Rate | 7 | 2020 | 1872 | 0.380 |
Why?
| Age Factors | 11 | 2022 | 3152 | 0.370 |
Why?
| Cohort Studies | 9 | 2025 | 5426 | 0.370 |
Why?
| Risk Factors | 14 | 2024 | 9786 | 0.370 |
Why?
| Neoplasm Metastasis | 3 | 2020 | 611 | 0.360 |
Why?
| Quality Improvement | 2 | 2018 | 1101 | 0.360 |
Why?
| Health Services | 1 | 2012 | 99 | 0.360 |
Why?
| Cross-Sectional Studies | 11 | 2023 | 5075 | 0.360 |
Why?
| Periodicals as Topic | 2 | 2023 | 204 | 0.350 |
Why?
| Patient Protection and Affordable Care Act | 3 | 2024 | 99 | 0.350 |
Why?
| Surgical Procedures, Operative | 2 | 2012 | 244 | 0.340 |
Why?
| Physician Self-Referral | 1 | 2010 | 1 | 0.340 |
Why?
| Social Class | 4 | 2022 | 259 | 0.340 |
Why?
| Intestinal Perforation | 3 | 2016 | 45 | 0.340 |
Why?
| Biomedical Research | 2 | 2020 | 640 | 0.330 |
Why?
| Models, Econometric | 6 | 2017 | 33 | 0.320 |
Why?
| Financing, Personal | 2 | 2019 | 26 | 0.320 |
Why?
| Waiting Lists | 1 | 2011 | 237 | 0.320 |
Why?
| Physicians | 1 | 2018 | 866 | 0.320 |
Why?
| Carcinoma, Squamous Cell | 3 | 2019 | 627 | 0.320 |
Why?
| Radiation Oncology | 1 | 2010 | 75 | 0.320 |
Why?
| Recovery of Function | 1 | 2013 | 642 | 0.320 |
Why?
| Data Collection | 3 | 2014 | 650 | 0.320 |
Why?
| Astrocytoma | 1 | 2010 | 115 | 0.320 |
Why?
| Costs and Cost Analysis | 2 | 2022 | 201 | 0.320 |
Why?
| Gastrointestinal Hemorrhage | 3 | 2016 | 122 | 0.310 |
Why?
| Colorado | 3 | 2025 | 4404 | 0.310 |
Why?
| Surveys and Questionnaires | 12 | 2018 | 5415 | 0.310 |
Why?
| Administration, Oral | 2 | 2023 | 787 | 0.310 |
Why?
| Propensity Score | 1 | 2010 | 264 | 0.300 |
Why?
| Dentists | 1 | 2008 | 19 | 0.300 |
Why?
| Persuasive Communication | 1 | 2008 | 14 | 0.300 |
Why?
| Dental Care | 1 | 2008 | 26 | 0.300 |
Why?
| Life Expectancy | 1 | 2008 | 60 | 0.300 |
Why?
| Oropharyngeal Neoplasms | 2 | 2018 | 48 | 0.300 |
Why?
| Multivariate Analysis | 9 | 2019 | 1499 | 0.290 |
Why?
| HIV Infections | 2 | 2022 | 2730 | 0.290 |
Why?
| Odds Ratio | 9 | 2014 | 1019 | 0.280 |
Why?
| Pneumonectomy | 1 | 2008 | 151 | 0.270 |
Why?
| Patient Education as Topic | 1 | 2011 | 737 | 0.260 |
Why?
| Depression | 4 | 2021 | 1317 | 0.260 |
Why?
| Likelihood Functions | 5 | 2021 | 137 | 0.250 |
Why?
| Confidence Intervals | 4 | 2013 | 317 | 0.250 |
Why?
| Time Factors | 11 | 2013 | 6555 | 0.250 |
Why?
| Women, Working | 2 | 2002 | 11 | 0.250 |
Why?
| Quality-Adjusted Life Years | 4 | 2017 | 106 | 0.250 |
Why?
| Education, Medical, Graduate | 1 | 2010 | 442 | 0.250 |
Why?
| Online Systems | 1 | 2005 | 22 | 0.240 |
Why?
| Cross Infection | 2 | 2017 | 217 | 0.240 |
Why?
| Colonic Diseases | 2 | 2016 | 32 | 0.240 |
Why?
| Myocardial Infarction | 3 | 2023 | 1021 | 0.240 |
Why?
| Disability Evaluation | 1 | 2007 | 285 | 0.240 |
Why?
| Cost Savings | 2 | 2018 | 78 | 0.240 |
Why?
| Anxiety | 3 | 2021 | 972 | 0.230 |
Why?
| Referral and Consultation | 1 | 2010 | 730 | 0.230 |
Why?
| Health Services Needs and Demand | 3 | 2017 | 263 | 0.230 |
Why?
| Adolescent | 14 | 2024 | 20412 | 0.230 |
Why?
| Leukemia, Myeloid, Acute | 1 | 2011 | 596 | 0.220 |
Why?
| Diabetes Mellitus, Type 2 | 3 | 2014 | 2442 | 0.220 |
Why?
| Models, Statistical | 4 | 2017 | 625 | 0.220 |
Why?
| Methicillin-Resistant Staphylococcus aureus | 2 | 2017 | 220 | 0.220 |
Why?
| Needs Assessment | 2 | 2024 | 357 | 0.220 |
Why?
| Probability | 5 | 2023 | 306 | 0.210 |
Why?
| Substance-Related Disorders | 3 | 1997 | 1020 | 0.210 |
Why?
| Physician-Patient Relations | 1 | 2008 | 540 | 0.210 |
Why?
| Head and Neck Neoplasms | 2 | 2019 | 544 | 0.210 |
Why?
| Hospitals, Public | 1 | 2023 | 26 | 0.210 |
Why?
| Community-Based Participatory Research | 1 | 2024 | 148 | 0.210 |
Why?
| Sex Factors | 6 | 2024 | 1970 | 0.200 |
Why?
| Forecasting | 5 | 2016 | 361 | 0.200 |
Why?
| Treatment Outcome | 11 | 2019 | 10219 | 0.200 |
Why?
| Economics, Medical | 1 | 2022 | 4 | 0.200 |
Why?
| Migraine Disorders | 1 | 2024 | 101 | 0.200 |
Why?
| Age Distribution | 4 | 2020 | 373 | 0.200 |
Why?
| Hormones | 1 | 2023 | 141 | 0.200 |
Why?
| Carcinoma | 2 | 2017 | 214 | 0.200 |
Why?
| Staphylococcal Infections | 2 | 2017 | 389 | 0.200 |
Why?
| Risk Assessment | 6 | 2022 | 3262 | 0.190 |
Why?
| Salaries and Fringe Benefits | 1 | 2002 | 55 | 0.190 |
Why?
| Health Behavior | 2 | 2019 | 743 | 0.190 |
Why?
| Ambulatory Care Facilities | 1 | 2024 | 226 | 0.190 |
Why?
| Proportional Hazards Models | 5 | 2019 | 1198 | 0.190 |
Why?
| Colonic Polyps | 2 | 2014 | 87 | 0.190 |
Why?
| Intensive Care Units | 2 | 2017 | 735 | 0.190 |
Why?
| Food Supply | 1 | 2022 | 73 | 0.190 |
Why?
| Bisexuality | 1 | 2022 | 30 | 0.190 |
Why?
| Incidence | 5 | 2022 | 2641 | 0.190 |
Why?
| Analgesics, Opioid | 2 | 2021 | 913 | 0.190 |
Why?
| Hospital Charges | 3 | 2003 | 42 | 0.190 |
Why?
| Smoking | 2 | 2019 | 1500 | 0.190 |
Why?
| Neoplasm Recurrence, Local | 3 | 2021 | 958 | 0.190 |
Why?
| Insulin, Isophane | 1 | 2001 | 21 | 0.180 |
Why?
| Brain Neoplasms | 1 | 2010 | 1145 | 0.180 |
Why?
| Retrospective Studies | 13 | 2024 | 14522 | 0.180 |
Why?
| Evidence-Based Medicine | 2 | 2016 | 712 | 0.180 |
Why?
| Internet | 1 | 2005 | 618 | 0.180 |
Why?
| Homosexuality, Male | 1 | 2022 | 176 | 0.170 |
Why?
| Decision Making | 2 | 2005 | 863 | 0.170 |
Why?
| Hospitalization | 5 | 2016 | 2057 | 0.170 |
Why?
| Kentucky | 1 | 2020 | 38 | 0.170 |
Why?
| Delayed Diagnosis | 1 | 2020 | 79 | 0.170 |
Why?
| Population Surveillance | 2 | 2022 | 439 | 0.170 |
Why?
| California | 2 | 2018 | 400 | 0.170 |
Why?
| Benzodiazepines | 1 | 2021 | 134 | 0.160 |
Why?
| Sample Size | 1 | 2000 | 116 | 0.160 |
Why?
| Stress, Psychological | 2 | 2021 | 1068 | 0.160 |
Why?
| Carrier State | 2 | 2017 | 60 | 0.160 |
Why?
| Regression Analysis | 5 | 2021 | 997 | 0.160 |
Why?
| Feasibility Studies | 1 | 2023 | 869 | 0.160 |
Why?
| Ownership | 2 | 2010 | 87 | 0.160 |
Why?
| Patient Care Team | 1 | 2024 | 600 | 0.160 |
Why?
| Infection Control | 2 | 2017 | 141 | 0.160 |
Why?
| Patient Selection | 3 | 2010 | 661 | 0.160 |
Why?
| Exercise Therapy | 1 | 2023 | 412 | 0.160 |
Why?
| Language Development Disorders | 1 | 2019 | 46 | 0.150 |
Why?
| Child | 7 | 2024 | 20884 | 0.150 |
Why?
| Diabetes Mellitus | 3 | 2018 | 1001 | 0.150 |
Why?
| Activities of Daily Living | 2 | 2010 | 382 | 0.150 |
Why?
| Los Angeles | 2 | 2015 | 63 | 0.150 |
Why?
| National Cancer Institute (U.S.) | 3 | 2023 | 43 | 0.150 |
Why?
| Anthracyclines | 3 | 2023 | 49 | 0.150 |
Why?
| Taxoids | 3 | 2023 | 98 | 0.150 |
Why?
| Cancer Pain | 1 | 2018 | 27 | 0.150 |
Why?
| Carboplatin | 1 | 2018 | 139 | 0.150 |
Why?
| Radiotherapy, Adjuvant | 1 | 2019 | 208 | 0.150 |
Why?
| Cetuximab | 1 | 2018 | 94 | 0.150 |
Why?
| Stroke | 2 | 2024 | 1071 | 0.150 |
Why?
| Hyperlipidemias | 1 | 2019 | 126 | 0.150 |
Why?
| Infant, Newborn | 4 | 2020 | 5756 | 0.150 |
Why?
| Ireland | 2 | 2016 | 27 | 0.140 |
Why?
| Research Design | 4 | 2007 | 1045 | 0.140 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2019 | 430 | 0.140 |
Why?
| Unemployment | 2 | 2009 | 43 | 0.140 |
Why?
| Financing, Government | 1 | 2017 | 43 | 0.140 |
Why?
| Managed Care Programs | 1 | 2018 | 133 | 0.140 |
Why?
| Inpatients | 2 | 2012 | 475 | 0.140 |
Why?
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2017 | 55 | 0.140 |
Why?
| Patient Discharge | 1 | 2023 | 836 | 0.140 |
Why?
| Hypertension | 2 | 2024 | 1243 | 0.140 |
Why?
| Combined Modality Therapy | 4 | 2019 | 1203 | 0.140 |
Why?
| Hospital Costs | 2 | 2011 | 115 | 0.130 |
Why?
| Public Health Practice | 1 | 2017 | 64 | 0.130 |
Why?
| Patient Rights | 2 | 2019 | 11 | 0.130 |
Why?
| Psychiatric Department, Hospital | 1 | 1996 | 14 | 0.130 |
Why?
| Attitude to Health | 3 | 2019 | 433 | 0.130 |
Why?
| Cisplatin | 1 | 2018 | 299 | 0.130 |
Why?
| Heart Failure | 2 | 2023 | 2133 | 0.130 |
Why?
| Drug Therapy | 1 | 2017 | 80 | 0.130 |
Why?
| Sex Distribution | 3 | 2020 | 360 | 0.130 |
Why?
| Language | 1 | 2019 | 283 | 0.130 |
Why?
| Child Behavior | 1 | 1998 | 236 | 0.130 |
Why?
| Clinical Competence | 2 | 2014 | 1017 | 0.130 |
Why?
| Lymph Nodes | 1 | 2019 | 472 | 0.130 |
Why?
| Hypoglycemic Agents | 2 | 2018 | 1221 | 0.130 |
Why?
| Self Efficacy | 1 | 2019 | 377 | 0.130 |
Why?
| Ambulatory Surgical Procedures | 1 | 2016 | 58 | 0.120 |
Why?
| Smoking Cessation | 1 | 2019 | 408 | 0.120 |
Why?
| Neonatal Abstinence Syndrome | 1 | 1996 | 23 | 0.120 |
Why?
| Patient Admission | 1 | 1997 | 183 | 0.120 |
Why?
| Child, Preschool | 4 | 2020 | 10490 | 0.120 |
Why?
| Colorectal Surgery | 1 | 2015 | 22 | 0.120 |
Why?
| Minority Groups | 1 | 2017 | 249 | 0.120 |
Why?
| Residence Characteristics | 2 | 2008 | 331 | 0.120 |
Why?
| Follow-Up Studies | 6 | 2019 | 4894 | 0.110 |
Why?
| Antineoplastic Agents, Hormonal | 1 | 2015 | 155 | 0.110 |
Why?
| Child Development | 1 | 2019 | 460 | 0.110 |
Why?
| Metformin | 1 | 2018 | 318 | 0.110 |
Why?
| Mastectomy, Segmental | 3 | 2009 | 86 | 0.110 |
Why?
| National Health Programs | 1 | 2014 | 17 | 0.110 |
Why?
| Infant | 3 | 2020 | 8995 | 0.110 |
Why?
| Patient Satisfaction | 2 | 2013 | 633 | 0.110 |
Why?
| Pennsylvania | 2 | 2024 | 108 | 0.110 |
Why?
| Autism Spectrum Disorder | 1 | 2019 | 388 | 0.110 |
Why?
| Systems Integration | 1 | 2013 | 37 | 0.110 |
Why?
| Pilot Projects | 3 | 2021 | 1592 | 0.110 |
Why?
| Computer Simulation | 2 | 2023 | 939 | 0.110 |
Why?
| Cerebrovascular Disorders | 1 | 2014 | 90 | 0.110 |
Why?
| Health Status Indicators | 1 | 2014 | 166 | 0.100 |
Why?
| Kaplan-Meier Estimate | 3 | 2021 | 851 | 0.100 |
Why?
| Quality of Health Care | 2 | 2008 | 604 | 0.100 |
Why?
| Helping Behavior | 1 | 2013 | 20 | 0.100 |
Why?
| Intensive Care Units, Neonatal | 1 | 1996 | 226 | 0.100 |
Why?
| Prospective Studies | 3 | 2017 | 7135 | 0.100 |
Why?
| Medical Audit | 1 | 2013 | 74 | 0.100 |
Why?
| Occupations | 1 | 2012 | 42 | 0.100 |
Why?
| Mandatory Programs | 1 | 2012 | 15 | 0.100 |
Why?
| Maryland | 3 | 1997 | 46 | 0.100 |
Why?
| Insurance, Pharmaceutical Services | 1 | 2012 | 23 | 0.100 |
Why?
| Pregnancy, Unwanted | 1 | 2012 | 14 | 0.100 |
Why?
| Life Tables | 2 | 2008 | 18 | 0.100 |
Why?
| Exercise | 2 | 2023 | 1928 | 0.100 |
Why?
| Cause of Death | 1 | 2014 | 395 | 0.100 |
Why?
| Cost Control | 1 | 2012 | 39 | 0.100 |
Why?
| Goals | 2 | 2023 | 159 | 0.100 |
Why?
| Community Health Services | 1 | 2013 | 228 | 0.090 |
Why?
| Self Disclosure | 1 | 2011 | 62 | 0.090 |
Why?
| Contraception Behavior | 1 | 2012 | 98 | 0.090 |
Why?
| Mental Disorders | 2 | 1997 | 1034 | 0.090 |
Why?
| Sepsis | 1 | 2017 | 575 | 0.090 |
Why?
| Contraceptive Agents, Female | 1 | 2012 | 78 | 0.090 |
Why?
| Retreatment | 1 | 2011 | 70 | 0.090 |
Why?
| Educational Status | 1 | 2013 | 471 | 0.090 |
Why?
| Case-Control Studies | 3 | 2024 | 3378 | 0.090 |
Why?
| Video Recording | 1 | 2011 | 163 | 0.090 |
Why?
| Pregnancy Complications | 1 | 1996 | 493 | 0.090 |
Why?
| Insulin | 1 | 2001 | 2326 | 0.090 |
Why?
| Mastectomy | 1 | 2011 | 132 | 0.090 |
Why?
| Economics, Nursing | 1 | 2010 | 1 | 0.090 |
Why?
| Stress, Physiological | 1 | 2013 | 414 | 0.090 |
Why?
| Guideline Adherence | 1 | 2014 | 527 | 0.080 |
Why?
| Interinstitutional Relations | 1 | 2010 | 54 | 0.080 |
Why?
| Reproducibility of Results | 3 | 2010 | 3080 | 0.080 |
Why?
| Access to Information | 1 | 2010 | 47 | 0.080 |
Why?
| Consumer Behavior | 1 | 1990 | 66 | 0.080 |
Why?
| Sentinel Surveillance | 1 | 2009 | 42 | 0.080 |
Why?
| Bone Marrow Transplantation | 1 | 2011 | 277 | 0.080 |
Why?
| Standard of Care | 1 | 2010 | 71 | 0.080 |
Why?
| Occult Blood | 1 | 2009 | 30 | 0.080 |
Why?
| Insurance Claim Reporting | 1 | 2009 | 22 | 0.080 |
Why?
| Ohio | 1 | 2009 | 152 | 0.080 |
Why?
| Private Sector | 1 | 2009 | 50 | 0.080 |
Why?
| Comparative Effectiveness Research | 1 | 2010 | 150 | 0.080 |
Why?
| Models, Theoretical | 1 | 2013 | 546 | 0.080 |
Why?
| Sex Characteristics | 2 | 2022 | 736 | 0.080 |
Why?
| Physical Exertion | 1 | 2010 | 205 | 0.080 |
Why?
| Linear Models | 1 | 2011 | 819 | 0.080 |
Why?
| Bias | 1 | 2010 | 197 | 0.080 |
Why?
| Home Nursing | 1 | 2008 | 26 | 0.080 |
Why?
| Gastrointestinal Neoplasms | 1 | 2009 | 72 | 0.080 |
Why?
| Women's Health | 2 | 2012 | 364 | 0.080 |
Why?
| Psychometrics | 1 | 2013 | 696 | 0.080 |
Why?
| Reimbursement Mechanisms | 1 | 2009 | 84 | 0.080 |
Why?
| Education, Professional | 1 | 2008 | 18 | 0.070 |
Why?
| Data Interpretation, Statistical | 1 | 2010 | 337 | 0.070 |
Why?
| Health Care Surveys | 1 | 2010 | 557 | 0.070 |
Why?
| Radiotherapy | 1 | 2008 | 185 | 0.070 |
Why?
| Self Care | 1 | 2010 | 363 | 0.070 |
Why?
| Pain | 2 | 2010 | 787 | 0.070 |
Why?
| Chi-Square Distribution | 1 | 2008 | 515 | 0.070 |
Why?
| Leukemia | 1 | 2008 | 229 | 0.060 |
Why?
| Pulmonary Disease, Chronic Obstructive | 1 | 2014 | 984 | 0.060 |
Why?
| Cognition Disorders | 1 | 2010 | 505 | 0.060 |
Why?
| Lung Diseases | 1 | 2012 | 741 | 0.060 |
Why?
| National Institutes of Health (U.S.) | 1 | 2006 | 122 | 0.060 |
Why?
| Charities | 1 | 2005 | 11 | 0.060 |
Why?
| Empirical Research | 1 | 2005 | 21 | 0.060 |
Why?
| Hospice Care | 1 | 2007 | 192 | 0.060 |
Why?
| Diabetes Mellitus, Type 1 | 1 | 2001 | 3628 | 0.060 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2010 | 1365 | 0.060 |
Why?
| Diagnosis-Related Groups | 1 | 2003 | 29 | 0.050 |
Why?
| Resource Allocation | 1 | 2003 | 39 | 0.050 |
Why?
| Florida | 2 | 2014 | 93 | 0.050 |
Why?
| Pandemics | 2 | 2022 | 1491 | 0.050 |
Why?
| Prevalence | 1 | 2010 | 2564 | 0.050 |
Why?
| Causality | 1 | 2023 | 117 | 0.050 |
Why?
| Health Surveys | 2 | 2007 | 493 | 0.050 |
Why?
| Social Security | 1 | 2002 | 5 | 0.050 |
Why?
| Markov Chains | 2 | 2017 | 117 | 0.050 |
Why?
| Selection Bias | 1 | 2002 | 37 | 0.050 |
Why?
| Motor Activity | 1 | 2007 | 676 | 0.050 |
Why?
| Interviews as Topic | 1 | 2005 | 704 | 0.050 |
Why?
| Sampling Studies | 1 | 2002 | 96 | 0.050 |
Why?
| Mastectomy, Radical | 1 | 2001 | 2 | 0.050 |
Why?
| Palliative Care | 1 | 2007 | 702 | 0.050 |
Why?
| Diagnostic Tests, Routine | 1 | 2002 | 104 | 0.050 |
Why?
| Insulin, Long-Acting | 1 | 2001 | 62 | 0.040 |
Why?
| Family Characteristics | 1 | 2002 | 179 | 0.040 |
Why?
| Pancreatic Neoplasms | 1 | 2008 | 880 | 0.040 |
Why?
| Arrhythmias, Cardiac | 1 | 2023 | 320 | 0.040 |
Why?
| Insulin Glargine | 1 | 2001 | 81 | 0.040 |
Why?
| Normal Distribution | 1 | 2000 | 21 | 0.040 |
Why?
| Drug Evaluation | 1 | 2000 | 82 | 0.040 |
Why?
| Diffusion of Innovation | 1 | 2001 | 97 | 0.040 |
Why?
| Clinical Trials as Topic | 1 | 2004 | 1005 | 0.040 |
Why?
| Severity of Illness Index | 1 | 2008 | 2739 | 0.040 |
Why?
| Nursing Research | 1 | 2000 | 47 | 0.040 |
Why?
| Presenteeism | 1 | 2019 | 5 | 0.040 |
Why?
| Etidronic Acid | 1 | 1998 | 5 | 0.040 |
Why?
| Alendronate | 1 | 1998 | 15 | 0.040 |
Why?
| Informed Consent | 1 | 2000 | 166 | 0.040 |
Why?
| Federal Government | 1 | 2018 | 27 | 0.040 |
Why?
| Osteoporosis, Postmenopausal | 1 | 1998 | 39 | 0.040 |
Why?
| Receptors, Estrogen | 1 | 2021 | 422 | 0.040 |
Why?
| Controlled Before-After Studies | 1 | 2017 | 14 | 0.040 |
Why?
| Lymphatic Metastasis | 1 | 2019 | 320 | 0.040 |
Why?
| Hyperglycemia | 1 | 2001 | 327 | 0.040 |
Why?
| Lymph Node Excision | 1 | 2019 | 164 | 0.040 |
Why?
| Smoking Prevention | 1 | 1998 | 163 | 0.040 |
Why?
| Estrogen Replacement Therapy | 1 | 1998 | 137 | 0.040 |
Why?
| Spinal Fractures | 1 | 1998 | 83 | 0.030 |
Why?
| Tennessee | 1 | 2017 | 43 | 0.030 |
Why?
| Puberty | 1 | 1998 | 143 | 0.030 |
Why?
| Ecosystem | 1 | 2022 | 560 | 0.030 |
Why?
| Diagnosis, Dual (Psychiatry) | 1 | 1997 | 36 | 0.030 |
Why?
| Chemoradiotherapy | 1 | 2018 | 208 | 0.030 |
Why?
| Patient Isolation | 1 | 2017 | 16 | 0.030 |
Why?
| Alzheimer Disease | 1 | 2002 | 514 | 0.030 |
Why?
| Catheter-Related Infections | 1 | 2017 | 72 | 0.030 |
Why?
| Biopsy, Needle | 1 | 2017 | 188 | 0.030 |
Why?
| Patient Dropouts | 1 | 1997 | 64 | 0.030 |
Why?
| Utilization Review | 1 | 1996 | 36 | 0.030 |
Why?
| Epidemiological Monitoring | 1 | 2017 | 50 | 0.030 |
Why?
| Arizona | 1 | 1996 | 78 | 0.030 |
Why?
| Bacteriological Techniques | 1 | 2017 | 69 | 0.030 |
Why?
| Health Policy | 1 | 2019 | 353 | 0.030 |
Why?
| Drug Administration Schedule | 1 | 2018 | 767 | 0.030 |
Why?
| Anticholesteremic Agents | 1 | 2018 | 150 | 0.030 |
Why?
| Dyslipidemias | 1 | 2018 | 177 | 0.030 |
Why?
| Hospitals, Community | 1 | 1996 | 48 | 0.030 |
Why?
| Schools | 1 | 2000 | 443 | 0.030 |
Why?
| Obstetric Labor, Premature | 1 | 1996 | 35 | 0.030 |
Why?
| Neoplasm Invasiveness | 1 | 2017 | 481 | 0.030 |
Why?
| Health Resources | 2 | 2009 | 114 | 0.030 |
Why?
| Telemedicine | 1 | 2023 | 792 | 0.030 |
Why?
| Antihypertensive Agents | 1 | 2018 | 485 | 0.030 |
Why?
| Protoporphyrins | 1 | 1993 | 16 | 0.030 |
Why?
| Acute Disease | 1 | 1996 | 979 | 0.030 |
Why?
| Learning Curve | 1 | 2014 | 69 | 0.030 |
Why?
| Lead | 1 | 1993 | 56 | 0.030 |
Why?
| Opioid-Related Disorders | 1 | 2021 | 483 | 0.030 |
Why?
| Immunohistochemistry | 1 | 2017 | 1685 | 0.030 |
Why?
| Sensitivity and Specificity | 3 | 2009 | 1843 | 0.030 |
Why?
| Societies, Medical | 1 | 2016 | 744 | 0.020 |
Why?
| Community Participation | 1 | 2013 | 125 | 0.020 |
Why?
| Calcium | 1 | 1998 | 1212 | 0.020 |
Why?
| General Surgery | 1 | 2014 | 153 | 0.020 |
Why?
| Risk | 1 | 2014 | 855 | 0.020 |
Why?
| Gastroenterology | 1 | 2014 | 175 | 0.020 |
Why?
| Pregnancy | 2 | 2012 | 6417 | 0.020 |
Why?
| Cooperative Behavior | 1 | 2013 | 433 | 0.020 |
Why?
| Hepatitis B | 1 | 1991 | 66 | 0.020 |
Why?
| Work Capacity Evaluation | 1 | 2010 | 11 | 0.020 |
Why?
| Contraception | 1 | 2012 | 153 | 0.020 |
Why?
| Prognosis | 1 | 2019 | 3774 | 0.020 |
Why?
| Budgets | 1 | 2009 | 12 | 0.020 |
Why?
| Sigmoidoscopy | 1 | 2009 | 11 | 0.020 |
Why?
| Leadership | 1 | 2013 | 357 | 0.020 |
Why?
| Task Performance and Analysis | 1 | 2010 | 173 | 0.020 |
Why?
| Ambulatory Care | 1 | 2013 | 506 | 0.020 |
Why?
| Meta-Analysis as Topic | 1 | 2009 | 170 | 0.020 |
Why?
| Prostatectomy | 1 | 2009 | 103 | 0.020 |
Why?
| Age of Onset | 1 | 2009 | 495 | 0.020 |
Why?
| Occupational Exposure | 1 | 1991 | 299 | 0.020 |
Why?
| Psychology | 1 | 2008 | 82 | 0.020 |
Why?
| Demography | 1 | 2008 | 279 | 0.020 |
Why?
| Mortality | 1 | 2008 | 307 | 0.020 |
Why?
| Lifting | 1 | 2006 | 4 | 0.020 |
Why?
| Least-Squares Analysis | 1 | 2006 | 79 | 0.020 |
Why?
| Illinois | 1 | 2006 | 42 | 0.020 |
Why?
| Telephone | 1 | 2007 | 167 | 0.020 |
Why?
| Body Weight | 1 | 1990 | 940 | 0.020 |
Why?
| Patient Compliance | 1 | 2009 | 565 | 0.020 |
Why?
| Prejudice | 1 | 2006 | 70 | 0.020 |
Why?
| Burnout, Professional | 1 | 2010 | 405 | 0.010 |
Why?
| Myocardial Revascularization | 1 | 2003 | 72 | 0.010 |
Why?
| Statistics, Nonparametric | 1 | 2003 | 419 | 0.010 |
Why?
| Vaccination | 1 | 1991 | 1347 | 0.010 |
Why?
| Behavior | 1 | 2002 | 93 | 0.010 |
Why?
| Episode of Care | 1 | 2001 | 7 | 0.010 |
Why?
| Decision Trees | 1 | 2001 | 90 | 0.010 |
Why?
| Drug Prescriptions | 1 | 2002 | 248 | 0.010 |
Why?
| Cardiac Catheterization | 1 | 2003 | 520 | 0.010 |
Why?
| Reoperation | 1 | 2001 | 541 | 0.010 |
Why?
| Neuropsychological Tests | 1 | 2002 | 1017 | 0.010 |
Why?
| Estrogens | 1 | 1998 | 347 | 0.010 |
Why?
| Drug Therapy, Combination | 1 | 1998 | 1042 | 0.010 |
Why?
| Estradiol | 1 | 1998 | 494 | 0.010 |
Why?
| Lead Poisoning | 1 | 1993 | 19 | 0.010 |
Why?
| ROC Curve | 1 | 1993 | 503 | 0.010 |
Why?
| Reference Values | 1 | 1993 | 794 | 0.010 |
Why?
| Program Evaluation | 1 | 1991 | 875 | 0.000 |
Why?
|
|
Bradley's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|